There is a webinar available online given by the lead investigator Dr. Hoffman at Tufts. He said the indications they chose (7 of them) were chosen because the diseases have human parallels. Their goal is to not only develop treatments for animals but also to lay the groundwork to launch human INDs based on the results. He feels that their approach of treating animals (peoples real pets) with naturally occurring diseases provides better indications of efficacy than does testing on rodents that are engineered to have particular diseases. So even though they are performing vet trials they are very focused on the human application of the therapy.
Just think, if human cells work well in dogs they'll probably even work better in humans.
Go easy on the resident multi-aliases STEM pumper. What he lacks in brain power he tries to make up for in his persistent spamming of pump messages.
ACT already has financed with Lincoln. This deal looks to be about the same.
ISCO is down to a market cap of $12 million and it doesn't look like they have the funds to file an IND. ACTC has a market cap of $220 million and just hired a top notch CEO. ISCO's issues aren't related to Lincoln.
Kolbert issue a sell recommendation on CUR when it was trading at 80 cents with a price target of 25 cents.
Seeking Alpha? Now that's a reliable source for investment information. LOL
They have stock promoters writing articles.
LOL. Here comes the dilution!
Irish, will your husband be able to be treated locally soon or do you need to wait until the Geron phase 2 trial starts?
The company would be worth exactly what it is worth today which is about $190 million.
If you want to know the share price you might need to go to school and learn how to multiply.
So far some STEM patients have improved sensory function after treatment and CUR hasn't started treating patients in their spinal cord trial yet. CUR's animal studies and human ALS patients show great promise. Time will tell.
Never been done before? Are you kidding?
It's the same procedure they have used in ALS patients and it has restored motor skills in some. In one case a patient went from using a cane to walking 5Ks to raise money for ALS. Google Ted Harada ALS.
I suspect the stem cells are pretty much the same since STEM licensed the IP from 2 of the 3 researchers and CUR licensed it from the other researcher who was left off the patent hence we have the non-stop spam about the legal dispute. CUR's procedure is considerably different. They have a device that injects directly into the spinal cord and they plan to span the injury site with multiple injections. It restored motor function in animal models and it has improved motor skills in ALS patients.
I think they still have a 0.25 price target they set when CUR was trading at 0.80
The problem is the first page of the message board is half filled with ignored messages. Yahoo still displays the messages.
I agree. It would be great to see hippocampus growth but I doubt that with 28 days of dosing there would be much if any. I think we will have to wait until phase 2 for that. If they did observe growth in this phase 1 that would be huge.